Subcutaneous · Amylin analog
MET233
2 trials in this molecule. Source: ClinicalTrials.gov, as of July 1, 2026.
Trials
2
Active
1
Recruiting
1
Completed
1
Sites
1
Countries
1
Endpoints
25
Composite endpoints
0
Distinct sites and countries across this molecule's trials. A site running several of its trials counts once, matching the map.
Development
Where the program stands
Trials by phase
Phase 1
1
Phase 1/2
1
Trials by status
Recruiting
1
Completed
1
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Weight & body composition
13
Safety / tolerability / PK
11
Other (unclassified)
1
Most-measured metrics
Top 20 metrics across this asset's endpoints
Trials
Programs for this asset
Every trial for this molecule, with the same search, filters, and sort as the Trials tab.
⌘K
2 of 2
| Asset / Population | Key I/E criterion | Evidence | ||||||
|---|---|---|---|---|---|---|---|---|
| NCT06924320A Study of MET233 in Combination With MET097 in Individuals With Obesity or Overweight With or Without Diabetes | MET097 / PF-08653944, MET233 Obesity / overweight, Type 2 diabetes | BMI 27-38 | Ph 1/2 | Recruiting | 1 | Sep 2026 | — | |
| NCT07022977A Study of MET233 in Individuals With Obesity or Overweight | MET233 Obesity / overweight | BMI 27-38 | Ph 1 | Completed | 1 | Apr 2026 | — |